Pharma Research Library | Pharma Info Index Research | Innovation | Opportunities |
ABOUT AUTHOR
Meera Kumari1, Arun Prasad1, Subha Ganguly2*
1Department of Veterinary Microbiology, College of Veterinary Science & Animal Husbandry, Birsa Agricultural University, Kanke, Ranchi – 834 006, Jharkhand, India
2AICRP-PHT (ICAR), Department of Fish Processing Technology, Faculty of Fishery Sciences, West Bengal University of Animal and Fishery Sciences, P.O. Panchasayar, Chakgaria, Kolkata -700 094, WB, India
Abstract
In the present study, 24 unvaccinated healthy pups of either sex preferably in the age group of 8- 18 week were be enrolled and divided in to 4 groups, each contained 6 pups. The 1st group was administered with Megavac 6, 2nd group with Vanguard 5L, 3rd group with Nobivac DHPPiL anti-canine parvovirus vaccines and the 4th group was considered as control. Blood was collected from all the pups on 0th day and vaccinated (treatment groups) on the same day. On the 28th day blood was collected from all the pups followed by administration of the booster dose to all the treatment groups. Again on 35th day only blood was collected from each group without vaccination. From the present study, it was observed that the efficacy of Megavac 6 was significantly (P<0.01) higher as compared to Vanguard 5L and Nobivac DHPPiL. All the three vaccines were safe and did not show any adverse reaction during the entire period of study. The overall health status of the vaccinated animals was sound and better than control pups.
Keywords: Canine parvovirus, Pups, Vaccines
